Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113274 - RANK ANTAGONISTS AND USES THEREFOR

Publication Number WO/2020/113274
Publication Date 11.06.2020
International Application No. PCT/AU2019/051330
International Filing Date 05.12.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 37/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
CPC
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 16/468
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
Applicants
  • THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU]/[AU]
Inventors
  • DOUGALL, Bill
  • AHERN, Elizabeth
Agents
  • DAVIES COLLISON CAVE PTY LTD
Priority Data
62/775,80305.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RANK ANTAGONISTS AND USES THEREFOR
(FR) ANTAGONISTES DE RANK ET LEURS UTILISATIONS
Abstract
(EN)
Disclosed are antigen-binding molecules that antagonize one or more functions of receptor activator of NF-κΒ (RANK) as well as methods of their manufacture and use. Applications are also disclosed in which these antagonist antigen-binding molecules are used in compositions and methods for treating or inhibiting the development of conditions associated with activation of the RANK ligand (RANKL) / RANK signaling pathway, for stimulating or augmenting immunity, for inhibiting the development or progression of immunosuppression or tolerance to a tumor and for inhibiting the development, progression or recurrence of cancer.
(FR)
L'invention concerne des molécules de liaison à l'antigène qui ont un effet antagoniste sur une ou plusieurs fonctions d'un activateur du récepteur de NF-κΒ (RANK), ainsi que des procédés de fabrication et d'utilisation de celles-ci. L'invention concerne également des utilisations de ces molécules de liaison à un antigène antagonistes qui sont utilisées dans des compositions et des méthodes pour traiter ou inhiber le développement d'états pathologiques associés à l'activation du ligand RANK (RANKL)/RANK, pour stimuler ou augmenter l'immunité, pour inhiber le développement ou la progression d'une immunosuppression ou d'une tolérance à une tumeur et pour inhiber le développement, la progression ou la récurrence du cancer.
Latest bibliographic data on file with the International Bureau